Fusion Antibodies Share Discussion Threads

[superg1] 21/9/2020 08:49

Diverisfication

It was mentioned many times over the weekend, still not on the radar and a big signpost top suggest antibodies on the way.

It would be incredible if the big params didn't engage rapidly now with Fusion re Covid.

So that news to come.

There were a number of confided punters on 4D picking this up while the usual crew were oblivious.

Based on the underlying business, the share price and they lack of big spending needed, this is the lowest risk of the lot with a high chance of a good return without Covid in play.

Obviously there is more news to come.

[xtomo] 21/9/2020 08:49

Never read so much ramping. The current drop will continue as is typical in this type of share irrespective of what you say. Plenty of stock too as I got quote for £25K worth just now.

[tidy 2] 21/9/2020 08:46

I've topped up

[superg1] 21/9/2020 08:46

I like to keep an eye on the MMs. Wins still have some as they stepped over Shoc on the offer.

[diversification] 21/9/2020 08:43

Didn’t think I’d get an opportunity to buy more here. Just filled me boots. Unless I’m missing something, this is a perfect opportunity to add more prior to the therapeutic.

[tidy 2] 21/9/2020 08:40

Bonus top up this am

[amrishbhim] 21/9/2020 08:36

Roche, was the reason, another partnership. You will get a reply soon

[superg1] 21/9/2020 08:32

Wins clearly have some this morning.

The usual crew like Myles will not say anything about it until they have some (if that's their plan)

[superg1] 21/9/2020 08:32

Gimme

Going by linkedin they had the antigen success 2 months ago, so in theory the test results took 2 months but they could have cracked on with antibody generation in that time.


This is not different to 4D it seemed largely missed that they had an almost identical answer like Synairgen. Synairgen was flying getting all the publicity while 4D sat around 50p. About £160 now when eventually the punters caught on.

Both 4D and Syn are therapeutic options to recuse inflammation not stop covid.

Fusion is the full range.

I think they are the only share of the Covid crew that could produce the necessary antibodies to neutralise covid in the body, which is a much more exciting prospect.

Literally test trace and eliminate, as they say. They can produce the answer to the lot.

[cbeadle] 21/9/2020 08:30

This dip will be short lived and a buying opportunity before we take off again

[diversification] 21/9/2020 08:10

I think we will see money exiting Odx and coming into Fab looking at comparative market caps, a requirement to measure level of antibodies following a vaccine and the upside of a Neutralizing therapeutic to boot.

[gimmetheloot] 21/9/2020 08:03

I have emailed FAB asking if the RNS in Friday relates to ROCHE which I am sure it’s does . I will post reply here once I receive.

[diversification] 21/9/2020 07:30

No comment, anywhere, zilch!

This is still under the radar, nothing on Twitter, ADVFN, Lse, today.

Perfect.

Low float of 9/10m shares will see this continue to fly imo.

[gimmetheloot] 21/9/2020 00:51

This is a FAB & Roche collaboration deal. It’s simple. Same day same time RNS and FAB is a client of ROCHE. Both RNS are very very similar.

[20pc] 20/9/2020 23:14

So putting 2 & 2 together and coming up with 5.

It seems that with the Roche connections, they could have been one of the "external partners" referred to by Fusion that tested the antigens.

Then on the same day that Roche announce their "new quantitative antibody test" and state that their test "targets antibodies against the spike protein"

Fusion announce that “The Company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins” and

“The Company’s extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests”

Diversfication, I am just speculating, we know that FAB are working with 8 of the top 10 pharmas (if i recall correctly) Roche were 2nd biggest with $50B in March.

I am just excited that if FAB are supplying them it means that as of now we are already supplying on a "commercial basis".

Would love to know the commercial value probably never will know specifics, but if the connection is correct FAB have got off to a flying start.

[diversification] 20/9/2020 22:36

Perhaps the links to Roche has legs:

Roche announce the Elecsys test at 06:03 on the 18th September.

FAB put together an intraday RNS containing significant news at 09:31. Normally, significant updated such as trading updates, funding etc are well organized and announced at 07:00.

My point being why intraday? Did Roche announcement force Fab hands? Would the fact that they are working with Roche require an RNS?

Questions we need answering imo.

[superg1] 20/9/2020 21:23

Further comment via that route

Recent validation studies have found RBD proteins manufactured by Fusion Antibodies, to accurately detect the presence of SARS-Cov-2; In a range of over 100 positive and negative blood samples, our results correlated exactly with a leading certified benchmark test.

[superg1] 20/9/2020 21:21

This is shown as 2 months ago when they got the antigens that we saw in news Friday

[superg1] 20/9/2020 21:07

Just picking up on patents which involve Fusion staff.

Some for Roche and some for Purdue Pharma

[superg1] 20/9/2020 20:57

A comment on the web re Roche

Fusion offer their experts for patent applications

another that Fusion contributed to has been patented by Swiss giant Roche.

So it shows they are well known by the big names

[superg1] 20/9/2020 20:43

This was interesting in the results too re their link up with MAB discovery (created by ex Roche guys)

The MAB Discovery partnership continues as we work with them to deliver their antibodies onward towards clinical development. We maintain our interest in in several molecules developed by MAB Discovery and other customers and have added new milestones for customer projects completed during the year.

[superg1] 20/9/2020 20:36

Re

Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.


Clearly some sort of advantage over other tests too identifying the level of antibodies in a person post infection.

So covid tests, antibody tests, vaccine generation and covid neutralising.

Everything in one place.